Molecular Diagnostics

Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1



Metaplastic breast carcinoma encompasses a heterogeneous group of tumours with differentiation into squamous and/or spindle, chondroid, osseous or rhabdoid mesenchymal-looking elements. Emerging immunotherapies targeting Programmed Death Ligand 1 (PD-L1) and immune-suppressing T cells (Tregs) may benefit metaplastic breast cancer patients, which are typically chemo-resistant and do not express hormone therapy targets.


We evaluated the immunohistochemical expression of PD-L1 and FOXP3, and the extent of tumour infiltrating lymphocytes (TILs) in a large cohort of metaplastic breast cancers, with survival data.


Metaplastic breast cancers were significantly enriched for PD-L1 positive tumour cells, compared to triple-negative ductal breast cancers (P < 0.0001), while there was no significant difference in PD-L1 positive TILs. Metaplastic breast cancers were also significantly enriched for TILs expressing FOXP3, with FOXP3 positive intra-tumoural TILs (iTILs) associated with an adverse prognostic outcome (P = 0.0226). Multivariate analysis identified FOXP3 iTILs expression status as an important independent prognostic factor for patient survival.


Our findings indicate the clinical significance and prognostic value of FOXP3, PD-1/PD-L1 checkpoint and TILs in metaplastic breast cancer and confirm that a subset of metaplastics may benefit from immune-based therapies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Tumour Infiltrating Lymphocytes in MBC.
Fig. 2: PD-L1 expression and prognostic implications in MBC.
Fig. 3: FOXP3 expression and prognostic implications in MBC.
Fig. 4: WNT activity and expression of immune checkpoint markers in MBC.


  1. 1.

    Lakhani S. R., Ellis I. O., Schnitt S. J., Tan P. H., van de Vijver M. J. WHO Classification of Tumours of the Breast 4th edn (eds Bosman, F. T., Jaffe, E. S., Lakhani, S. R., Oghaki, H.) (IARC, Lyon, 2012).

  2. 2.

    Hennessy, B. T., Gonzalez-Angulo, A. M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J. S. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116–4124 (2009).

    CAS  Article  Google Scholar 

  3. 3.

    Lai, H. W., Tseng, L. M., Chang, T. W., Kuo, Y. L., Hsieh, C. M., Chen, S. T. et al. The prognostic significance of metaplastic carcinoma of the breast (MCB)-a case controlled comparison study with infiltrating ductal carcinoma. Breast 22, 968–973 (2013).

    Article  Google Scholar 

  4. 4.

    Nelson, R. A., Guye, M. L., Luu, T. & Lai, L. L. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann. Surg. Oncol. 22, 24–31 (2015).

    Article  Google Scholar 

  5. 5.

    Al-Hilli, Z., Choong, G., Keeney, M. G., Visscher, D. W., Ingle, J. N., Goetz, M. P. et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res. Treat. 176, 709–716 (2019).

    CAS  Article  Google Scholar 

  6. 6.

    Lehmann, B. D., Jovanovic, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y. et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11, e0157368 (2016).

    Article  Google Scholar 

  7. 7.

    Harano, K., Wang, Y., Lim, B., Seitz, R. S., Morris, S. W., Bailey, D. B. et al. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE 13, e0204513 (2018).

    Article  Google Scholar 

  8. 8.

    Weigelt, B., Kreike, B. & Reis-Filho, J. S. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat. 117, 273–280 (2009).

    CAS  Article  Google Scholar 

  9. 9.

    Weigelt, B., Ng, C. K., Shen, R., Popova, T., Schizas, M., Natrajan, R. et al. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. Mod. Pathol. 28, 340–351 (2015).

    CAS  Article  Google Scholar 

  10. 10.

    Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959–2966 (2014).

    Article  Google Scholar 

  11. 11.

    Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544–1550 (2014).

    CAS  Article  Google Scholar 

  12. 12.

    Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2015).

    CAS  Article  Google Scholar 

  13. 13.

    Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res 2, 361–370 (2014).

    CAS  Article  Google Scholar 

  14. 14.

    Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K. et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 69, 25–34 (2016).

    Article  Google Scholar 

  15. 15.

    Muenst, S., Schaerli, A. R., Gao, F., Daster, S., Trella, E., Droeser, R. A. et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 146, 15–24 (2014).

    CAS  Article  Google Scholar 

  16. 16.

    Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R. et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann. Oncol. 30, 405–411 (2019).

    CAS  Article  Google Scholar 

  17. 17.

    Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann. Oncol. 30, 397–404 (2019).

    CAS  Article  Google Scholar 

  18. 18.

    Joneja, U., Vranic, S., Swensen, J., Feldman, R., Chen, W., Kimbrough, J. et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J. Clin. Pathol. 70, 255–259 (2017).

    CAS  Article  Google Scholar 

  19. 19.

    Dill, E. A., Gru, A. A., Atkins, K. A., Friedman, L. A., Moore, M. E., Bullock, T. N. et al. PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am. J. Surg. Pathol. 41, 334–342 (2017).

    Article  Google Scholar 

  20. 20.

    Tray, N., Taff, J., Singh, B., Suh, J., Ngo, N., Kwa, M. et al. Metaplastic breast cancers: genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast 44, 29–32 (2018).

    Article  Google Scholar 

  21. 21.

    Adams, S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer 3, 8 (2017).

    Article  Google Scholar 

  22. 22.

    Shitara, K. & Nishikawa, H. Regulatory T cells: a potential target in cancer immunotherapy. Ann. N. Y Acad. Sci. 1417, 104–115 (2018).

    CAS  Article  Google Scholar 

  23. 23.

    Lee, S., Cho, E. Y., Park, Y. H., Ahn, J. S. & Im, Y. H. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 52, 73–81 (2013).

    CAS  Article  Google Scholar 

  24. 24.

    Yeong, J., Thike, A. A., Lim, J. C., Lee, B., Li, H., Wong, S. C. et al. Higher densities of Foxp3(+) regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res. Treat. 163, 21–35 (2017).

    CAS  Article  Google Scholar 

  25. 25.

    Shou, J., Zhang, Z., Lai, Y., Chen, Z. & Huang, J. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis. BMC Cancer 16, 687 (2016).

    Article  Google Scholar 

  26. 26.

    McCart Reed, A. E., Kalaw, E., Nones, K., Bettington, M., Lim, M., Bennett, J. et al. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. J. Pathol. 247, 214–227 (2019).

    CAS  Article  Google Scholar 

  27. 27.

    Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, tils in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv. Anat. Pathol. 24, 235–251 (2017).

    Article  Google Scholar 

  28. 28.

    Liu, S., Foulkes, W. D., Leung, S., Gao, D., Lau, S., Kos, Z. et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 16, 432 (2014).

    Article  Google Scholar 

  29. 29.

    Lacroix-Triki, M., Geyer, F. C., Lambros, M. B., Savage, K., Ellis, I. O., Lee, A. H. et al. beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod. Pathol. 23, 1438–1448 (2010).

    CAS  Article  Google Scholar 

  30. 30.

    Adwal, A., Croft, P. K.-D., Shakya, R., Lim, M., Kalaw, E., Taege, L. D. et al. Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer. Life Sci. Alliance. 3, e201900562 (2020).

    Article  Google Scholar 

  31. 31.

    Castagnoli, L., Cancila, V., Cordoba-Romero, S. L., Faraci, S., Talarico, G., Belmonte, B. et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene 38, 4047–4060 (2019).

    CAS  Article  Google Scholar 

  32. 32.

    Kulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D. et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch. Pathol. Lab Med. 143, 330–337 (2019).

    CAS  Article  Google Scholar 

  33. 33.

    Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460–2467 (2016).

    CAS  Article  Google Scholar 

  34. 34.

    Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B. et al. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Res. 21, 72 (2019).

    Article  Google Scholar 

  35. 35.

    Tong, M., Wang, J., He, W., Wang, Y., Pan, H., Li, D. et al. Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res. 10, 4501–4507 (2018).

    CAS  Article  Google Scholar 

  36. 36.

    Liu, C., Workman, C. J. & Vignali, D. A. Targeting regulatory T cells in tumors. FEBS J. 283, 2731–2748 (2016).

    CAS  Article  Google Scholar 

  37. 37.

    Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J. et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4, 134ra62 (2012).

    Article  Google Scholar 

  38. 38.

    Li, Z., Dong, P., Ren, M., Song, Y., Qian, X., Yang, Y. et al. PD-L1 Expression Is associated with tumor FOXP3+ regulatory T-Cell infiltration of breast cancer and poor prognosis of patient. J Cancer7, 784–793 (2016).

    CAS  Article  Google Scholar 

Download references


We thank the patients and their families and acknowledge the support of Metro North Hospital and Health Services in the collection of the clinical subject data and clinical subject materials.

Author information




A.E.M.R., P.T.S. and S.R.L. conceived experiments, analysed data, and drafted the paper. A.E.M.R., E.K., M.L., I.G., J.K., A.S., L.T., K.J., J.B. carried out experiments. K.F., C.N. collated samples and clinical data. J.K. and J.S. analysed data. S.R.L., S.A.O’.T., R.Y., G.H., S.F., P.H.T., D.P., R.P., G.T., N.P., K.J., M.B., A.S., L.T. and J.B. performed pathology review. All authors were involved in writing the paper and had final approval of the submitted and published versions.

Corresponding authors

Correspondence to Sunil R. Lakhani or Amy E. McCart Reed.

Ethics declarations

Ethics approval and consent to participate

Human research ethics committees approved the use of all clinical samples and data (The University of Queensland (2005000785) and the Royal Brisbane and Women’s Hospital (2005/022)). Signed consent for study participants was waived due to the archival nature of the material. The study was performed in accordance with Declaration of Helsinki.

Data availability

All data is included in the publication.

Competing interests

The authors declare no competing interests.

Funding information

S.A.O’.T. is funded by the National Breast Cancer Foundation (PRAC‐16‐006 and IIRS-19-084) and the Sydney Breast Cancer Foundation. Pathology Queensland—Study Education and Research Committee supported the study. The study was funded by a Cancer Australia/National Breast Cancer Foundation PdCCRS grant (APP1082435) and an NHMRC Program Grant (APP1113867).

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kalaw, E., Lim, M., Kutasovic, J.R. et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. Br J Cancer (2020).

Download citation